AAD 2026: Galderma Showcases Latest Evidence Supporting Its Full-Spectrum, Science-Driven Solutions
From its Therapeutic Dermatology portfolio, Galderma will present data on the efficacy and safety of Nemluvio庐 (nemolizumab) in different patient populations with moderate-to-severe atopic dermatitis, including late-breaking data in pediatric patients, and share four posters on AKLIEF庐 (trifarotene)1-8
Additional presentations related to Dermatological Skincare will explore how artificial intelligence can identify high-risk factors for sensitive skin and Cetaphil庐 in different skin types9
Data from Galderma
来源：
作者：
